| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 |
| XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 |
| XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 |
| XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
| XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
| XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
| XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
| XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
| XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
| XW013S6 | Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
| XW013S9 | Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
| XW013T6 | Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
| XW013U6 | Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
| XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
| XW013W5 | Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
| XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
| XW01X27 | Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 |
| XW020D8 | Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8 |
| XW023S6 | Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 |
| XW023T6 | Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 |
| XW023U6 | Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 |
| XW023V7 | Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW023W7 | Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW023X7 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW023Y7 | Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW03306 | Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW03308 | Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW03326 | Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW03336 | Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW03357 | Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW03358 | Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW03366 | Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW03367 | Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW03368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW03372 | Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2 |
| XW03377 | Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW03378 | Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW03387 | Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW03388 | Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW03396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW03398 | Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW033A6 | Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033A7 | Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3 |
| XW033B6 | Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033B7 | Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033C6 | Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033D6 | Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033E5 | Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033E6 | Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033F3 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3 |
| XW033F5 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033F6 | Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033G6 | Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033H5 | Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033H6 | Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033J7 | Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033K5 | Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033K9 | Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
| XW033L6 | Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
| XW033L7 | Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033N5 | Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033P9 | Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
| XW033Q5 | Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033Q9 | Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
| XW033R9 | Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
| XW033S5 | Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033U5 | Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW033W5 | Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
| XW04306 | Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW04308 | Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8 |
| XW04326 | Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW04336 | Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW04357 | Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW04358 | Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8 |
| XW04366 | Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW04367 | Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW04368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 |
| XW04372 | Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2 |
| XW04377 | Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW04378 | Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8 |
| XW04387 | Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW04388 | Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8 |
| XW04396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW04398 | Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8 |
| XW043A6 | Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043A7 | Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3 |
| XW043B6 | Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043B7 | Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043C6 | Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043D6 | Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043E5 | Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043E6 | Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043F3 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3 |
| XW043F5 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043F6 | Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043G5 | Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043G6 | Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043H5 | Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043H6 | Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043J7 | Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043K5 | Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043K9 | Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9 |
| XW043L6 | Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6 |
| XW043L7 | Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043N5 | Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 |
| XW043P9 | Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9 |
| XW043Q5 | Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043Q9 | Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9 |
| XW043R9 | Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9 |
| XW043S5 | Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043U5 | Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW043W5 | Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
| XW053T9 | Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9 |
| XW097M5 | Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5 |
| XW0DX38 | Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8 |
| XW0DX66 | Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6 |
| XW0DX82 | Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2 |
| XW0DXF5 | Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW0DXJ5 | Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW0DXJ9 | Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9 |
| XW0DXK8 | Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8 |
| XW0DXL5 | Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW0DXM6 | Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6 |
| XW0DXN9 | Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9 |
| XW0DXR5 | Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW0DXR7 | Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7 |
| XW0DXT5 | Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW0DXV5 | Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW0G738 | Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 |
| XW0G7K8 | Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 |
| XW0G7M6 | Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6 |
| XW0G7R7 | Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7 |
| XW0G886 | Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6 |
| XW0H738 | Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 |
| XW0H7K8 | Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 |
| XW0H7M6 | Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6 |
| XW0H7R7 | Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7 |
| XW0H7X8 | Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 |
| XW0H886 | Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6 |
| XW0Q316 | Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6 |
| XW0V0P7 | Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7 |